|Biliary Cirrhosis Market Segment Forecasts up to 2020, Research Reports ...|
Biliary cirrhosis, also widely known as primary biliary cirrhosis (PBC), is an autoimmune disease in which small bile ducts in the liver are damaged. These ducts in the liver are caused due to the accumulation of bile inside the liver and its pressure ...
Medgadget.com (blog) - Wed, 02 Sep 2015 11:33
|UDCA reduces risk for recurrent cirrhosis after liver transplantation|
Researchers collected and analyzed data of 90 patients enrolled across five French and Swiss transplant centers between 1988 and 2010 who underwent liver transplant for primary biliary cirrhosis (PBC). Nineteen patients underwent preventive therapy ...
Healio - Tue, 01 Sep 2015 09:52
|FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment ...|
PBC is a rare liver disease that primarily results from autoimmune destruction of the bile ducts that transport bile acids out of the liver, resulting in cholestasis. It is primarily a disease of women, afflicting approximately one in 1,000 women over ...
GlobeNewswire (press release) - Mon, 31 Aug 2015 04:03
|FDA grants priority review of obeticholic acid for cirrhosis|
“Despite current treatment, PBCremains a leading cause of liver transplant among women, so there is a clear ongoing high unmet medical need for new therapies for patients with [primary biliary cirrhosis],” Mark Pruzanski, MD, president and CEO of ...
Healio - Wed, 02 Sep 2015 08:22
|US FDA grants Priority Review for Intercept's obeticholic acid to treat ...|
pharmabiz.com - Wed, 02 Sep 2015 05:22
|Intercept's (ICPT) OCA Under Priority Review in the US|
Zacks.com - Tue, 01 Sep 2015 13:57
|Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Given $165-$493 PT Range|
Markets Daily - Wed, 02 Sep 2015 09:18
|Wedbush Reiterates Buy Rating for Intercept Pharmaceuticals (ICPT)|
Financial Wisdom Works - Wed, 02 Sep 2015 08:22
|Intercept Pharmaceuticals Inc (NASDAQ:ICPT) FDA Accepted Review for ...|
Street Report - Tue, 01 Sep 2015 06:16
|ICP increases risk for liver and biliary cancer, CVD|
Researchers in Sweden found that women with intrahepatic cholestasis of pregnancy had an increased risk for developing late liver and biliary tree cancer, immune-mediated diseases and cardiovascular disease, according to published findings in the ...
Healio - Thu, 13 Aug 2015 11:56
|Intrahepatic cholestasis of pregnancy linked with liver cancer|
Medical Xpress - Wed, 12 Aug 2015 05:26
|SLA/LP antibodies, early cirrhosis indicate poor outcomes in autoimmune hepatitis|
Antibodies for the soluble liver antigen/liver pancreas antigen and diagnosis of cirrhosis before 18 years of age were found to be major risk factors for poor short- and long-term outcomes in patients with autoimmune hepatitis, including a reduced ...
Healio - Wed, 02 Sep 2015 13:03
|Monday Morning Pre-Market Insights: Seadrill Ltd (SDRL), Intercept ...|
... jumped 2.15% in pre-market trading to $78.77 following news that the FDA granted priority review for the biopharmaceutical company's pipeline drug; Obeticholic acid, or OCA, used to treat patients with the liver disease primary biliary cirrhosis (PBC).
Smarter Analyst - Mon, 31 Aug 2015 05:11
|Case Study: PBC Responds to Anti-TNF Agent|
Drugs targeting tumor necrosis factor (TNF) may be an effective option in treating primary biliary cirrhosis (PBC), an autoimmune disorder of the liver frequently associated with rheumatoid arthritis. That's the implication of a case report published ...
MedPage Today - Tue, 25 Aug 2015 13:26